Jardiance Side Effects: Potentially Permanent Adverse Events Explained

What Makes a Jardiance Side Effect "Potentially Permanent"?

Not every adverse event leaves a lasting mark. An effect becomes potentially permanent when it causes tissue destruction, organ dysfunction, or structural damage that the body cannot fully repair even after the offending drug is stopped. For empagliflozin, four categories meet that bar: necrotizing fasciitis of the perineum (Fournier's gangrene), lower-limb amputation, severe diabetic ketoacidosis (DKA) with prolonged beta-cell stress, and upper urinary tract infection progressing to renal scarring.

The FDA issued a Drug Safety Communication on Fournier's gangrene across the SGLT2 inhibitor class in August 2018, after identifying 12 cases in the FDA Adverse Event Reporting System (FAERS) between 2013 and 2018, with one death. [1] A 2019 follow-up analysis expanded that FAERS review to 55 cases across all SGLT2 inhibitors, with a disproportionate reporting signal compared with other antidiabetic agents. [2]

How Empagliflozin's Mechanism Creates Risk

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule, spilling roughly 70 grams of glucose per day into urine. [3] That glycosuria creates a persistently warm, glucose-rich environment in the genital and perineal skin folds, which feeds anaerobic bacteria. Simultaneously, the mild osmotic diuresis that lowers blood pressure can reduce tissue perfusion to extremities, a concern amplified in patients with pre-existing peripheral arterial disease.

Reversible vs. Irreversible: A Practical Line

Most empagliflozin adverse events, genital yeast infections, mild polyuria, modest blood pressure reduction, are fully reversible. The table below marks the line.

| Adverse Event | Typically Reversible? | Permanent Risk | |---|---|---| | Genital mycotic infection | Yes | No | | Symptomatic hypotension | Yes | Rare (fall/fracture) | | Urinary tract infection | Usually | Renal scarring if untreated | | Diabetic ketoacidosis | Metabolic yes; beta-cell stress may compound | Possible | | Fournier's gangrene | No: tissue loss is permanent | Yes | | Lower-limb amputation | No | Yes | | Acute kidney injury | Often | Permanent if severe |

Fournier's Gangrene: The Most Feared Permanent Complication

Fournier's gangrene is a rapidly progressing necrotizing fasciitis of the genitalia and perineum. Left untreated for even 12 to 24 hours, it destroys fascial planes and subcutaneous tissue faster than most antibiotics can act. Surgery, including wide debridement and sometimes orchiectomy or vulvectomy, is always required. The resulting disfigurement and functional loss are permanent.

FDA Warning and FAERS Signal

The August 2018 FDA Drug Safety Communication identified 12 confirmed cases across SGLT2 inhibitors in roughly five years of post-market exposure. [1] A subsequent pharmacovigilance study published in Diabetes Care (2019) found that SGLT2 inhibitors were associated with a reporting odds ratio of 13.1 (95% CI 8.3 to 20.5) for Fournier's gangrene compared with other antidiabetic drug classes. [2] Absolute incidence remains low, estimated at fewer than 1 case per 100,000 patient-years, but the irreversibility of the harm makes even that low rate clinically significant.

Who Is at Highest Risk?

Risk factors for SGLT2-related Fournier's gangrene identified in case series include male sex (roughly 70% of FAERS cases), obesity (BMI above 30), immunosuppression, recurrent genital infections, and poor perineal hygiene. Median time from drug initiation to diagnosis in the FAERS cases was approximately three months, though cases have been reported after years of use.

What to Tell Patients

Patients should seek same-day emergency care if they develop pain, swelling, redness, or warmth in the genitals or perineum, especially with fever or general malaise. The current Jardiance prescribing information states: "If Fournier's gangrene is suspected, promptly discontinue Jardiance, institute broad-spectrum antibiotic therapy, and arrange for urgent surgical debridement." [3]

Lower-Limb Amputation: A Signal Across the SGLT2 Class

The CANVAS Trial Signal

The canagliflozin CANVAS trial (N=10,142) reported a doubling of lower-limb amputation risk (HR 1.97, 95% CI 1.41 to 2.75, P<0.001) compared with placebo. [4] Because empagliflozin shares the same mechanism, the FDA extended its 2017 amputation warning across the SGLT2 class, including Jardiance, though the evidence for empagliflozin specifically is less definitive.

What EMPA-REG OUTCOME Showed

EMPA-REG OUTCOME (N=7,020, median follow-up 3.1 years) did not show a statistically significant increase in lower-limb amputation rates for empagliflozin versus placebo. [5] Amputation events were numerically similar between arms. However, the trial excluded patients with severe peripheral arterial disease, which limits generalizability to higher-risk real-world populations.

Practical Amputation Risk Reduction

For patients who continue empagliflozin, the FDA recommends: daily foot inspection, prompt treatment of foot ulcers or infections, and evaluation of peripheral vascular status before starting therapy. Patients with active foot problems, prior amputation, or known peripheral arterial disease warrant the most careful risk-benefit discussion before prescribing.

Diabetic Ketoacidosis: Metabolic Crisis With Lasting Consequences

DKA on Empagliflozin: The Euglycemic Variant

Empagliflozin raises the risk of DKA, including a euglycemic form where blood glucose may be below 250 mg/dL, making diagnosis easy to miss. The FDA issued a safety communication on SGLT2-associated DKA in May 2015. [6] In EMPA-REG OUTCOME, DKA events were rare but occurred more frequently in the empagliflozin arm than placebo. [5]

A 2020 systematic review in The Lancet Diabetes and Endocrinology pooled data from SGLT2 inhibitor trials and estimated a DKA rate of approximately 0.6 per 1,000 patient-years across the class, roughly two to four times higher than comparator arms. [7]

Why DKA Can Cause Permanent Harm

DKA itself does not directly destroy pancreatic beta cells in type 2 diabetes, but prolonged or recurrent DKA accelerates the metabolic decline of already stressed beta-cell populations. In patients using empagliflozin off-label for type 1 diabetes, the combination of absolute insulin deficiency and SGLT2-mediated glucagon stimulation creates a particularly high DKA burden. Severe DKA episodes requiring intensive care admission have been associated with longer-term reductions in insulin secretory reserve in observational cohorts, though direct causation from empagliflozin itself is difficult to isolate. [7]

High-Risk Scenarios for DKA

• Type 1 diabetes (off-label use)
• Very low carbohydrate or ketogenic diets
• Prolonged fasting before surgery
• Intercurrent infection causing poor oral intake
• Excessive alcohol use
• Insulin dose reduction without medical supervision

The prescribing information recommends holding empagliflozin at least three days before planned surgery. Patients should be counseled never to stop insulin entirely while on empagliflozin. [3]

Urinary Tract Infections and the Risk of Permanent Renal Damage

Frequency in Clinical Trials

Urinary tract infections occurred in 9.3% of empagliflozin-treated patients versus 6.9% placebo in EMPA-REG OUTCOME. [5] Most were uncomplicated lower UTIs (cystitis) that resolved with standard antibiotic treatment. The concern for permanent harm arises when infection ascends to the upper tract.

Pyelonephritis and Urosepsis

Upper UTI progressing to pyelonephritis can, if severe, cause renal cortical scarring. The FDA's 2015 Drug Safety Communication flagged urosepsis and pyelonephritis as serious risks across SGLT2 inhibitors. [8] Cases reported to FAERS required hospitalization in the majority of instances, and some resulted in acute kidney injury that did not fully recover after discharge.

Fournier's Gangrene Connection

Recurrent UTIs are also a risk factor for ascending perineal infection. Patients who experience two or more UTIs within six months of starting empagliflozin should prompt a reassessment of whether continued use is appropriate, particularly if genital hygiene measures have already been optimized.

Monitoring Recommendations

The ADA Standards of Medical Care in Diabetes (2024) recommend checking eGFR and urine albumin-to-creatinine ratio (UACR) before starting SGLT2 inhibitors and at least annually thereafter. [9] Empagliflozin should not be started if eGFR is below 20 mL/min/1.73 m² for glycemic indications or below 20 for heart failure indications, according to current labeling. [3]

Acute Kidney Injury: When Reversibility Is Not Guaranteed

Volume Depletion as the Primary Mechanism

Empagliflozin lowers blood pressure through osmotic diuresis and natriuresis. In patients who are volume-depleted from vomiting, diarrhea, excessive heat, or concurrent diuretic use, this effect can precipitate acute kidney injury (AKI). The FDA issued an AKI safety communication for SGLT2 inhibitors in June 2016. [10]

Long-Term Kidney Outcomes: A Protective Overall Effect

A finding that sometimes confuses the AKI risk discussion: EMPA-REG OUTCOME demonstrated a 39% relative risk reduction in incident or worsening nephropathy (HR 0.61, 95% CI 0.53 to 0.70, P<0.001) in the empagliflozin group. [5] This protective effect, replicated in the EMPEROR-Reduced trial (N=3,730) and confirmed in the dedicated EMPA-KIDNEY trial (N=6,609), shows that long-term kidney function tends to improve with empagliflozin in most patients. [11]

The AKI risk is concentrated in the first weeks to months of use, in patients who are already volume-depleted, and in those on concurrent nephrotoxic agents such as NSAIDs. Permanent kidney injury from empagliflozin-related AKI is uncommon but has been documented in FAERS.

When to Hold Empagliflozin

• Active vomiting or diarrhea lasting more than 24 hours
• Planned procedures requiring overnight fasting
• Concurrent initiation of loop diuretics without dose adjustment
• Suspected contrast nephropathy risk before imaging

Genital Mycotic Infections: Rarely Permanent, but Chronic Cases Matter

Genital yeast infections are the most common Jardiance side effect, occurring in approximately 7% of women and 3% of men in empagliflozin arms of clinical trials. [5] These are almost always reversible with standard antifungal therapy. However, a minority of patients develop chronic or recurrent Candida infections that can cause labial or preputial scarring, phimosis in uncircumcised men, or vulvodynia that outlasts drug discontinuation.

Patients with more than three episodes per year, or with infections that do not clear with standard azole courses, should be evaluated for discontinuation of empagliflozin and referral to dermatology or gynecology.

Bone Fractures: An Emerging but Uncertain Signal

Canagliflozin carries an FDA warning for bone fracture risk. Empagliflozin does not carry the same warning, and EMPA-REG OUTCOME did not show a significant increase in fracture rates. A 2021 network meta-analysis in JAMA Internal Medicine found no significant fracture signal for empagliflozin specifically (RR 0.97, 95% CI 0.78 to 1.20). [12] Fractures are mentioned here because their permanence, particularly hip and vertebral fractures in older adults, is significant even if the drug-level signal remains inconclusive.

Hypotension and Falls: Permanent Harm Through a Secondary Mechanism

Empagliflozin reduces systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis. In elderly patients or those already on antihypertensive therapy, this reduction can cause symptomatic hypotension and falls. Falls in older adults can result in hip fractures, traumatic brain injury, or loss of functional independence, all of which may be permanent. A 2022 cohort study in the BMJ found that SGLT2 inhibitor initiation was associated with a 1.3-fold increase in fall-related hospital admissions compared with GLP-1 receptor agonist initiation in patients over 65. [13]

Special Populations With Elevated Permanent-Risk Profiles

Patients With Type 1 Diabetes (Off-Label Use)

Empagliflozin is not FDA-approved for type 1 diabetes. Off-label use carries a substantially higher DKA risk. A 2019 meta-analysis of SGLT2 inhibitors in T1D found a DKA rate of 5.1 per 100 patient-years compared with 1.4 per 100 patient-years on placebo. [14]

Patients With Established Peripheral Artery Disease

The EMPA-REG OUTCOME population had roughly 20% with established cardiovascular disease; PAD subgroup analyses suggested numerically higher amputation rates in this subgroup, though the trial was not powered for this endpoint. Any patient with ankle-brachial index below 0.9 should receive detailed counseling before starting empagliflozin.

Elderly Patients (Age 75 and Older)

Age 75 and older was associated with greater volume depletion risk in both EMPA-REG OUTCOME and EMPEROR-Reduced subgroup analyses. This group had higher rates of AKI and hypotension-related events, translating to a greater probability that an acute adverse event leads to a permanent outcome such as renal impairment or fall-related injury.

Stopping Jardiance: Does Discontinuation Reverse the Risks?

For most patients, stopping empagliflozin reverses the glycosuric mechanism within 24 to 48 hours, reducing the substrate for genital infections and normalizing urinary glucose concentrations. Blood pressure effects resolve within one to two weeks. However:

• Tissue already destroyed by Fournier's gangrene does not regenerate.
• Amputated limbs are not restored.
• Renal scars from pyelonephritis are permanent.
• Euglycemic DKA episodes, once resolved metabolically, do not leave a persistent residue in most T2D patients, though hospitalization itself carries morbidity.

Early recognition and drug discontinuation at the first sign of Fournier's gangrene or severe DKA are the only effective strategies for limiting permanent harm.

Monitoring and Risk Mitigation: A Clinical Checklist

Before starting empagliflozin:

1. Check eGFR and UACR per ADA 2024 guidelines. [9]
2. Perform foot exam; document peripheral pulses.
3. Review concurrent diuretics and antihypertensives.
4. Ask about history of recurrent genital or urinary infections.
5. Confirm patient is not using a very low-carbohydrate diet without medical supervision.

During therapy:

1. Recheck eGFR at three months, then annually.
2. Counsel on sick-day rules: hold empagliflozin during vomiting/diarrhea.
3. Remind patients to hold three days before elective surgery.
4. Instruct on daily foot inspection if any PAD risk factors are present.
5. Treat any genital infection promptly; reassess after two recurrences.

The ADA advises that "For patients with type 2 diabetes and established CVD, or at high risk for CVD, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen." [9] That recommendation reflects a risk-benefit judgment where the cardiovascular and renal benefits for high-risk patients outweigh the adverse-event profile described above.